Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,122 shares of the pharmaceutical company’s stock after buying an additional 73 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Vertex Pharmaceuticals were worth $1,839,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Clearbridge Investments LLC grew its position in shares of Vertex Pharmaceuticals by 29.1% during the 1st quarter. Clearbridge Investments LLC now owns 5,521,210 shares of the pharmaceutical company’s stock valued at $1,186,453,000 after buying an additional 1,244,784 shares during the last quarter. Canada Pension Plan Investment Board grew its position in shares of Vertex Pharmaceuticals by 2,203.0% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,227,475 shares of the pharmaceutical company’s stock valued at $263,772,000 after buying an additional 1,174,177 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Vertex Pharmaceuticals by 134.6% during the 1st quarter. Ameriprise Financial Inc. now owns 1,918,067 shares of the pharmaceutical company’s stock valued at $412,162,000 after buying an additional 1,100,467 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Vertex Pharmaceuticals by 110.6% during the 1st quarter. ARK Investment Management LLC now owns 1,719,046 shares of the pharmaceutical company’s stock valued at $369,406,000 after buying an additional 902,852 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Vertex Pharmaceuticals by 34.1% during the 2nd quarter. Deutsche Bank AG now owns 2,733,910 shares of the pharmaceutical company’s stock valued at $551,238,000 after buying an additional 694,871 shares during the last quarter. Institutional investors and hedge funds own 88.63% of the company’s stock.

In related news, CEO Reshma Kewalramani acquired 10,000 shares of the stock in a transaction on Thursday, August 19th. The stock was purchased at an average price of $195.65 per share, for a total transaction of $1,956,500.00. Following the transaction, the chief executive officer now owns 69,511 shares of the company’s stock, valued at approximately $13,599,827.15. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.70% of the company’s stock.

Shares of VRTX stock opened at $181.34 on Thursday. Vertex Pharmaceuticals Incorporated has a 12-month low of $176.36 and a 12-month high of $275.75. The company has a market capitalization of $47.04 billion, a P/E ratio of 23.92, a P/E/G ratio of 1.77 and a beta of 0.63. The firm has a 50-day moving average price of $190.45 and a 200 day moving average price of $201.07. The company has a quick ratio of 4.43, a current ratio of 4.61 and a debt-to-equity ratio of 0.06.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, July 29th. The pharmaceutical company reported $3.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.86. Vertex Pharmaceuticals had a net margin of 29.80% and a return on equity of 29.73%. The firm had revenue of $1.79 billion during the quarter, compared to the consensus estimate of $1.71 billion. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 10.83 earnings per share for the current year.

VRTX has been the subject of several recent analyst reports. Stifel Nicolaus cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $244.00 to $213.00 in a research report on Thursday, September 9th. Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a research report on Monday, July 19th. They issued an “outperform” rating and a $252.00 target price for the company. SVB Leerink upped their target price on shares of Vertex Pharmaceuticals from $170.00 to $175.00 and gave the stock an “underperform” rating in a research report on Friday, July 30th. Morgan Stanley cut shares of Vertex Pharmaceuticals from an “equal weight” rating to an “underweight” rating and set a $202.00 target price for the company. in a research report on Tuesday, September 7th. Finally, Royal Bank of Canada upped their target price on shares of Vertex Pharmaceuticals from $246.00 to $248.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $264.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals, Inc is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

Featured Article: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.